

OCT 30 2008



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

 Sheet **1** of **5** Attorney Docket Number **38797-8004.US00**
38797-8004 US00
SB08A 5310771 1 (2)

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/Relevant Figures Appear
		Number	Kind Code (if known)			
	1.	US-5,770,578		Binder et al.	06-23-1998	
	2.	US-5,942,233		Chang	08-24-1999	
	3.	US-6,007,989		West et al.	12-28-1999	
	4.	US-6,126,942		Yang	10-03-2000	
	5.	US-6,190,678		Hasenoehrl et al.	02-20-2001	
	6.	US-6,277,396		Dente	08-21-2001	
	7.	US-6,346,539		Raman et al.	02-12-2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages-Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ² (if known)				
	8.	PCT	WO 99/35243	A3	Cold Spring Harbor Laboratory	07-15-1999		
	9.	PCT	WO 00/08135	A1	Geron Corporation	02-17-2000		
	10.	PCT	WO 00/31238	A2	Genetica Inc.	06-02-2000		
	11.	PCT	WO 01/01996	A1	University of Western Australia	01-11-2001		
	12.	PCT	WO 02/91999	A2	Geron Corporation	11-21-2002		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	13.	Bedir, E. et al., "Immunostimulatory effects of cycloartane-type triterpene glycosides from Astragalus species", <i>Biol. Pharm. Bull.</i> , 23(7):834-837 (2000).	
	14.	Bodnar, A. G. et al., "Extension of life-span by introduction of telomerase into normal human cells" <i>Science</i> , 279(5349):349-52 (1998).	
	15.	Calzada, L. et al., "Effect of tetracyclic triterpenes (argentatins A, B and D) on the estradiol receptor of hormone-dependent tumors of human breast", <i>Medical Science Research</i> , 23(12):815-16 (1995).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/562,374
Sheet	2	of	5	Filing Date	March 9, 2007
				First Named Inventor	Harley et al.
				Group Art Unit	1623
				Confirmation No.	7952
				Examiner Name	To be Assigned
				Attorney Docket Number	38797-8004.US00

38797-8004 US00 SB08A 5310771 1 (2) 1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. ²	T ⁶
	16.	Chiu, C. P. et al., "Replicative senescence and cell immortality: the role of telomeres and telomerase", <i>Proc. Soc. Exp. Biol. Med.</i> , <u>214</u> (2):99-106 (Feb 1997).	
	17.	Dagarag, M. et al., "Differential impairment of lytic and cytokine functions in senescent human immunodeficiency virus type 1-specific cytotox T lymphocytes", <i>Journal of Virology</i> , <u>77</u> (5):3077-83 (2003).	
	18.	Farwell, D. G. et al., "Genetic and epigenetic changes in human epithelial cells immortalized by telomerase", <i>American Journal of Pathology</i> , <u>156</u> (5):1537-47 (2000).	
	19.	Fujimoto, R. et al., "Expression of telomerase components in oral keratinocytes and squamous cell carcinomas", <i>Oral Oncology</i> , <u>37</u> (2):132-40 (2001).	
	20.	Funk, Walter D. et al., "Telomerase expression restores dermal integrity to in vitro- aged fibroblasts in a reconstituted skin model", <i>Experimental Cell Research</i> , <u>258</u> (2):270-278 (2000).	
	21.	Harle-Bachor, C. et al., "Telomerase activity in the regenerative basal layer of the epidermis in human skin and in immortal and carcinoma-derived skin keratinocytes", <i>Proc. Natl. Acad. Sci. USA</i> , <u>93</u> (13):6476-81 (1996).	
	22.	Harley, C. B. et al., "Telomeres shorten during ageing of human fibroblasts", <i>Nature</i> , <u>345</u> (6274):458-60 (1990).	
	23.	Henderson, S. et al., "In situ analysis of changes in telomere size during replicative aging and cell transformation", <i>Journal of Cell Biology</i> , <u>134</u> (1):1-12 (1996).	
	24.	Huang, Y. et al., "Selected non-timber forest products with medicinal applications from Jilin Province in China", Conference Title: Forest communities in the third millennium: Linking research, business, and policy toward a sustainable non-timber forest product sector; Kenora, Ontario, Canada, 1-4 October, 1999; General Technical Report- North Central Research Station, USDA Forest Service (No. NC-217): p. 93-101 (2000).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/562,374
Sheet	3	of	5	Filing Date	March 9, 2007
				First Named Inventor	Harley et al.
				Group Art Unit	1623
				Confirmation No.	7952
				Examiner Name	To be Assigned
				Attorney Docket Number	38797-8004.US00

38797-8004 US00 SB08A 5310771 1 (2) 1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. ²	
	25.	International Search Report for PCT application PCT/US2004/0202777 search report dated March 21, 2005, 2 pages (2005).	
	26.	Kaneko, M. et al., "Accelerated recovery from cyclophosphamide-induced leukopenia in mice administered a Japanese ethical herbal drug, <i>Hochu-ekki-to</i> ", <i>Immunopharmacology</i> , <u>44</u> (3):223-231 (1999).	
	27.	Kang, M. K. et al., "Replicative senescence of normal human oral keratinocytes is associated with the loss of telomerase activity without shortening of telomeres", <i>Cell Growth & Differentiation</i> , <u>9</u> (1):85-95 (1998).	
	28.	Khushbaktova, Z. A. et al., "Influence of cycloartanes from plants of the genus <i>Astragalus</i> and their synthetic analogs on the contractive function of the rnyocarbium and the activity of Na, K-ATPase", <i>Chemistry of Natural Compounds</i> , <u>30</u> (4):469-473 (1994).	
	29.	Kitagawa et al., "Saponin and Sapogenol XXXIV. Chemical Constituents of <i>Astragali Radix</i> , the Root of <i>Astragalus Membranaceus</i> Bunge (1). Cycloastragenol, the 9,19-Cyclolanostane-type Aglycone of Astragalosides, and the Artifact Aglycone Astragenol, <i>Chem. Pharm. Bull.</i> , <u>31</u> (2):689-697 (1983).	
	30.	Kitagawa et al., "Saponin and Sapogenol XXXV. Chemical Constituents of <i>Astragali Radix</i> , the Root of <i>Astragalus Membranaceus</i> Bunge (2). Astragalosides I, II and IV, Acetylastragaloside I and Isoastragalosides I and II, <i>Chem. Pharm. Bull.</i> , <u>31</u> (2):698-708 (1983).	
	31.	Kinjo, J. et al., "Anti-herpes virus activity of fabaceous triterpenoidal saponins", <i>Biological & Pharmaceutical Bulletin</i> <u>23</u> (7):887-9 (2000).	
	32.	Lee, K. M. et al., "Immortalization with telomerase of the Nestin-positive cells of the human pancreas", <i>Biochem Biophys Res Commun</i> , <u>301</u> (4):1038-44 (2003).	
	33.	Mattson, M. P. , "Emerging neuroprotective strategies for Alzheimer's disease: dietary restriction, telomerase activation, and stem cell therapy", <i>Experimental Gerontology</i> , <u>35</u> (4):489-502 (2000).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
				Application Number	10/562,374
				Filing Date	March 9, 2007
				First Named Inventor	Harley et al.
				Group Art Unit	1623
				Confirmation No.	7952
				Examiner Name	To be Assigned
				Attorney Docket Number	38797-8004.US00
Sheet	4	of	5	38797-8004 US00 SB08A 5310771 1 (2) 1	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. ²	T ⁶
	34.	Morales, C. P. et al., "Absence of cancer-associated changes in human fibroblasts immortalized with telomerase", <i>Nature Genetics</i> , <u>21</u> (1):115-8 (1999).	
	35.	Oda, K. et al., "Adjuvant and haemolytic activities of 47 saponins derived from medicinal and food plants", <i>Biological Chemistry</i> , <u>381</u> (1):67-74 (2000).	
	36.	Oh, H. and Schneider, M. D. , "The emerging role of telomerase in cardiac muscle cell growth and survival", <i>Journal of Molecular Cellular Cardiology</i> , <u>34</u> (7):717-24 (2002).	
	37.	Pistelli, L., et al., "Antimicrobial and antifungal activity of crude extracts and isolated saponins from <i>Astragalus verrucosus</i> ", <i>Fitoterapia</i> , <u>73</u> (4):336-339 (2002).	
	38.	Simonsen, J. L. et al., "Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells", <i>Nature Biotechnology</i> , <u>20</u> (6):592-6 (2002).	
	39.	Thomas, M. , Yang, L. , and Hornsby, P. J., "Formation of functional tissue from transplanted adrenocortical cells expressing telomerase reverse transcriptase", <i>Nature Biotechnology</i> , <u>18</u> (1):39-42 (2000).	
	40.	Vasa, M. et al., "Nitric oxide activates telomerase and delays endothelial cell senescence", <i>Circulation Research</i> , <u>87</u> (7):540-542 (2000).	
	41.	Wang, Y-P. et al., "Effect of astragaloside IV on T, B lymphocyte proliferation and peritoneal macrophage function in mice", <i>Acta Pharmacologica Sinica</i> , <u>23</u> (3): 263-6 (2002).	
	42.	Yang, J. et al., "Telomerized human microvasculature is functional in vivo", <i>Nature Biotechnology</i> , <u>19</u> (3):219-24 (2001).	
	43.	Yang, J., et al., "Human endothelial cell life extension by telomerase expression", <i>The Journal of Biological Chemistry</i> , <u>274</u> (37):26141-26148 (1999).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/562,374
				Filing Date	March 9, 2007
				First Named Inventor	Harley et al.
				Group Art Unit	1623
				Confirmation No.	7952
				Examiner Name	To be Assigned
				Attorney Docket Number	38797-8004.US00
Sheet	5	of	5	38797-8004 US00 SB08A 5310771 1 (2) 1	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. ²	T ⁶
	44.	Yasukawa, K. et al., "Sterol and triterpene derivatives from plants inhibit the effects of a tumor promoter, and sitosterol and betulinic acid inhibit tumor formation in mouse skin two-stage carcinogenesis", <i>Oncology</i> , <u>48</u> (1) :72-6 (1991).	
	45.	Yudoh, K. et al., "Reconstituting telomerase activity using the telomerase catalytic subunit prevents the telomere shorting and replicative senescence in human osteoblasts", <i>Journal of Bone and Mineral Research</i> , <u>16</u> (8):1453-1464 (2001).	
	46.	Zhang W. J. et al., "Regulation of the fibrinolytic potential of cultured human umbilical vein endothelial cells : astragaloside IV downregulates plasminogen activator inhibitor-1 and upregulates tissue-type plasminogen activator expression", <i>Journal of Vascular Research</i> , <u>34</u> (4):273-80 (1997).	
	47.	Zi-Pu, L. and Qian, C., "Effects of astragaloside IV on myocardial calcium transport and cardiac function in ischemic rats", <i>Acta Pharmacol Sin</i> <u>23</u> (10):898-904 (2002).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.